Today's knowledge of the parts of a pharmacokinetics and pharmacodynamic (PK/PD) system is increasingly detailed, and correspondingly complex models need to be devised for its description. The investigation of optimal experimental designs and the development of models which allow the incorporation of prior scientific knowledge and the integration of diverse pharmacological effects into a coherent picture of drug action is the main purpose of this grant proposal.
Aim 1 investigates experimental design problems associated with PK/PD models. We will develop new methods for sample size calculations in population PK/PD studies. We will also investigate optimal sampling and optimal dosage regimen designs for PK/PD models when complete prior knowledge on the parts of a model is not available. We will develop algorithms to produce optimal designs for standard widely used PK/PD models, and investigate the performance of optimized designs in respect to empirical, frequently used ones.
Aim 2 investigates specific applications of Bayesian analysis to complex physiologically based PK/PD models, concentrating on their performance in respect to semi empirical models, and their sensitivity to assumptions. We plan to develop and investigate the performance of novel Bayesian models for: (i) HIV-1 modeling in the presence of multi drug (HAART) therapy (incorporating virus phenotype, drug compliance and PK information), (ii) drug absorption using multi-site models and in-vivo/in vitro correlation, and (iii) in vitro/in vivo correlation of liposome distribution in anti-cancer therapy. Computer implementations of the models successfully developed will be provided.
Aim 3 will provide a Bayesian framework for model-independent representations that do not require the sophistication of physiological models but retain the capability to incorporate prior knowledge. We will first investigate estimation methods incorporating prior knowledge for deconvolution in linear systems and develop Bayesian Marcov Chain Monte Carlo (MCMC) methods to obtain the desired estimates (an unknown absorption or input rate function) and their posterior distribution. Second, we will extend these MCMC methodologies to non-linear systems, providing improved algorithms for the estimation of Volterra representations, and developing a general method (""""""""high order deconvolution"""""""") to estimate the input to a non linear system given its Volterra representation. Finally, we will develop a computer program for Bayesian linear and non-linear system analysis, which allows investigators to use the (model independent representations and MCMC-based methods we will investigate.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI050587-02
Application #
6662688
Study Section
Special Emphasis Panel (ZRG1-SNEM-5 (01))
Program Officer
Gezmu, Misrak
Project Start
2002-09-30
Project End
2007-03-31
Budget Start
2003-04-01
Budget End
2004-03-31
Support Year
2
Fiscal Year
2003
Total Cost
$264,688
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Pharmacy
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Frymoyer, Adam; Meng, Lina; Bonifacio, Sonia L et al. (2013) Gentamicin pharmacokinetics and dosing in neonates with hypoxic ischemic encephalopathy receiving hypothermia. Pharmacotherapy 33:718-26
Frymoyer, Adam; Verotta, Davide; Jacobson, Pamala et al. (2013) Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. Br J Clin Pharmacol 75:463-75
Frymoyer, A; Lee, S; Bonifacio, S L et al. (2013) Every 36-h gentamicin dosing in neonates with hypoxic-ischemic encephalopathy receiving hypothermia. J Perinatol 33:778-82
Dong, Betty J; Zheng, Yu; Hughes, Michael D et al. (2012) Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS 26:833-41
Verotta, Davide (2010) Fractional dynamics pharmacokinetics-pharmacodynamic models. J Pharmacokinet Pharmacodyn 37:257-76
Verotta, Davide (2010) Fractional compartmental models and multi-term Mittag-Leffler response functions. J Pharmacokinet Pharmacodyn 37:209-15; discussion 217-20
Chabas, D; Ness, J; Belman, A et al. (2010) Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology 74:399-405
Schwartz, J B; Verotta, D (2009) Population analyses of atorvastatin clearance in patients living in the community and in nursing homes. Clin Pharmacol Ther 86:497-502
Perger, Ludwig; Rentsch, Katharina M; Kullak-Ublick, Gerd A et al. (2009) Oral heroin in opioid-dependent patients: pharmacokinetic comparison of immediate and extended release tablets. Eur J Pharm Sci 36:421-32
Kshirsagar, Smita; Gear, Robert; Levine, Jon et al. (2008) A mechanistic model for the sex-specific response to nalbuphine and naloxone in postoperative pain. J Pharmacokinet Pharmacodyn 35:69-83

Showing the most recent 10 out of 18 publications